投融资数据库
免费查数据
注册送3天会员
首页>投融资
普祺医药
B轮
Beijing PrimeGene Therapeutics (also PrimeGene; Beijing Puqi Pharmaceutical Technology), founded in 2016, is a pharmaceutical company focused on developing therapies for the potential treatment of skin diseases, eye diseases as well as inflammatory and infectious diseases.Chifeng Saliont Pharmaceutical had been a majority owner of the company. However, by December 2022, the company had been operating as an independent business.In December 2022, the company completed series A+ financing of approximately RMB 100 million
基本信息
-
公司全称北京普祺医药科技股份有限公司
-
类型创新型药物研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数51~100人
-
地址北京市北京经济技术开发区经海三路105号院6号楼4层413室
-
联系电话01083141848
-
邮箱jiangyi@primegene.net
-
成立时间2016-09-25
投融资
-
2025-01-02
-
2024-12-25
-
2024-05-16
-
2024-01-23
-
2023-12-25
-
2023-12-25
-
2022-12-07
-
2022-11-24
-
2022-11-24
-
2021-05-20
-
2021-05-20
- 加载更多
相关投融资企业
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
收并购
Kronos Bio, Inc.于2017年6月2日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，致力于发现和开发新的癌症疗法，旨在通过针对失调转录的精确药物策略来改变患者的预后。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息